Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
Approximately 20% of breast cancers (BC) overexpress human epidermal growth factor receptor 2 (HER2). This subtype of BC is a clinically and biologically heterogeneous disease that was associated with an increased risk for the development of systemic and brain metastases and poor overall survival be...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/1/51 |
| _version_ | 1797626186265788416 |
|---|---|
| author | Kreina Sharela Vega Cano David Humberto Marmolejo Castañeda Santiago Escrivá-de-Romaní Cristina Saura |
| author_facet | Kreina Sharela Vega Cano David Humberto Marmolejo Castañeda Santiago Escrivá-de-Romaní Cristina Saura |
| author_sort | Kreina Sharela Vega Cano |
| collection | DOAJ |
| description | Approximately 20% of breast cancers (BC) overexpress human epidermal growth factor receptor 2 (HER2). This subtype of BC is a clinically and biologically heterogeneous disease that was associated with an increased risk for the development of systemic and brain metastases and poor overall survival before anti-HER2 therapies were developed. The standard of care was dual blockade with trastuzumab and pertuzumab as first-line followed by TDM-1 as second-line. However, with the advent of new HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors and antibody- drug conjugates, the clinical outcomes of patients with HER2-positive BC have changed dramatically in recent years, leading to a paradigm shift in the treatment of the disease. Notably, the development of new-generation ADCs has led to unprecedented results compared with T-DM1, currently establishing trastuzumab deruxtecan as a new standard of care in second-line. Despite the widespread availability of HER2-targeted therapies, patients with HER2-positive BC continue to face the challenges of disease progression, treatment resistance, and brain metastases. Response rate and overall life expectancy decrease with each additional line of treatment, and tumor heterogeneity remains an issue. In this review, we update the new-targeted therapeutic options for HER2-positive BC and highlight the future perspectives of treatment in this setting. |
| first_indexed | 2024-03-11T10:06:55Z |
| format | Article |
| id | doaj.art-81572b009d8a48b199650ffb1614c34e |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T10:06:55Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-81572b009d8a48b199650ffb1614c34e2023-11-16T15:00:57ZengMDPI AGCancers2072-66942022-12-011515110.3390/cancers15010051Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future TrendsKreina Sharela Vega Cano0David Humberto Marmolejo Castañeda1Santiago Escrivá-de-Romaní2Cristina Saura3Medical Oncology Department, Vall d’Hebron University Hospital, 08035 Barcelona, SpainMedical Oncology Department, Vall d’Hebron University Hospital, 08035 Barcelona, SpainMedical Oncology Department, Vall d’Hebron University Hospital, 08035 Barcelona, SpainMedical Oncology Department, Vall d’Hebron University Hospital, 08035 Barcelona, SpainApproximately 20% of breast cancers (BC) overexpress human epidermal growth factor receptor 2 (HER2). This subtype of BC is a clinically and biologically heterogeneous disease that was associated with an increased risk for the development of systemic and brain metastases and poor overall survival before anti-HER2 therapies were developed. The standard of care was dual blockade with trastuzumab and pertuzumab as first-line followed by TDM-1 as second-line. However, with the advent of new HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors and antibody- drug conjugates, the clinical outcomes of patients with HER2-positive BC have changed dramatically in recent years, leading to a paradigm shift in the treatment of the disease. Notably, the development of new-generation ADCs has led to unprecedented results compared with T-DM1, currently establishing trastuzumab deruxtecan as a new standard of care in second-line. Despite the widespread availability of HER2-targeted therapies, patients with HER2-positive BC continue to face the challenges of disease progression, treatment resistance, and brain metastases. Response rate and overall life expectancy decrease with each additional line of treatment, and tumor heterogeneity remains an issue. In this review, we update the new-targeted therapeutic options for HER2-positive BC and highlight the future perspectives of treatment in this setting.https://www.mdpi.com/2072-6694/15/1/51HER2 positivemetastatic breast cancertargeted therapiestrastuzumabantibody-drug conjugatestrastuzumab deruxtecan |
| spellingShingle | Kreina Sharela Vega Cano David Humberto Marmolejo Castañeda Santiago Escrivá-de-Romaní Cristina Saura Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends Cancers HER2 positive metastatic breast cancer targeted therapies trastuzumab antibody-drug conjugates trastuzumab deruxtecan |
| title | Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends |
| title_full | Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends |
| title_fullStr | Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends |
| title_full_unstemmed | Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends |
| title_short | Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends |
| title_sort | systemic therapy for her2 positive metastatic breast cancer current and future trends |
| topic | HER2 positive metastatic breast cancer targeted therapies trastuzumab antibody-drug conjugates trastuzumab deruxtecan |
| url | https://www.mdpi.com/2072-6694/15/1/51 |
| work_keys_str_mv | AT kreinasharelavegacano systemictherapyforher2positivemetastaticbreastcancercurrentandfuturetrends AT davidhumbertomarmolejocastaneda systemictherapyforher2positivemetastaticbreastcancercurrentandfuturetrends AT santiagoescrivaderomani systemictherapyforher2positivemetastaticbreastcancercurrentandfuturetrends AT cristinasaura systemictherapyforher2positivemetastaticbreastcancercurrentandfuturetrends |